A trial of mithramycin in the treatment of advanced malignant disease.
作者信息
Sewell I A, Ellis H
出版信息
Br J Cancer. 1966 Jun;20(2):256-63. doi: 10.1038/bjc.1966.32.
Abstract
摘要
相似文献
1
A trial of mithramycin in the treatment of advanced malignant disease.光辉霉素治疗晚期恶性疾病的试验。
Br J Cancer. 1966 Jun;20(2):256-63. doi: 10.1038/bjc.1966.32.
2
Preliminary clinical study of mithramycin (nsc-24559) in primary tumors of the central nervous system.光辉霉素（NSC-24559）治疗中枢神经系统原发性肿瘤的初步临床研究。
Cancer Chemother Rep. 1965 Dec;49:51-7.
3
Effect of mithramycin on calcium and hydroxyproline metabolism in patients with malignant disease.光辉霉素对恶性疾病患者钙和羟脯氨酸代谢的影响。
Br Med J. 1967 Feb 25;1(5538):474-7. doi: 10.1136/bmj.1.5538.474.
4
5
Mithramycin (NSC-24559) therapy for primary glioblastomas.光辉霉素（NSC-24559）治疗原发性胶质母细胞瘤。
Cancer Chemother Rep. 1965 Oct;48:59-63.
6
Weekly mitoxantrone in the treatment of advanced pancreatic carcinoma: a Southeastern Cancer Study Group Trial.
Cancer Treat Rep. 1986 Jul;70(7):929-30.
7
Treatment of advanced adenocarcinoma of the kidney with ICRF-187: a Southeastern Cancer Study Group Trial.用ICRF - 187治疗晚期肾腺癌：一项东南癌症研究组试验
Cancer Treat Rep. 1986 Jul;70(7):915-6.
8
Inflammatory bowel disease workshop. Vail, Colorado, March 22 and 23, 1998. Management of fistula disease.炎症性肠病研讨会。科罗拉多州韦尔，1998年3月22日和23日。瘘管病的管理
Inflamm Bowel Dis. 1998 Nov;4(4):302-7. doi: 10.1002/ibd.3780040409.
9
Phase II evaluation of mitoxantrone in advanced carcinoma of the stomach: a Southeastern Cancer Study Group Trial.
Cancer Treat Rep. 1986 Aug;70(8):1043-4.
10
A clinical trial of mithramycin in the treatment of advanced malignant disease.光辉霉素治疗晚期恶性疾病的临床试验。
Br J Cancer. 1968 Jun;22(2):176-83. doi: 10.1038/bjc.1968.25.
引用本文的文献
1
Mithramycin and Analogs for Overcoming Cisplatin Resistance in Ovarian Cancer.用于克服卵巢癌顺铂耐药性的光神霉素及其类似物
Biomedicines. 2021 Jan 12;9(1):70. doi: 10.3390/biomedicines9010070.
2
Severe Hepatotoxicity of Mithramycin Therapy Caused by Altered Expression of Hepatocellular Bile Transporters.米托蒽醌治疗导致肝细胞胆汁转运蛋白表达改变引起的严重肝毒性。
Mol Pharmacol. 2019 Aug;96(2):158-167. doi: 10.1124/mol.118.114827. Epub 2019 Jun 7.
3
Mithramycin Depletes Specificity Protein 1 and Activates p53 to Mediate Senescence and Apoptosis of Malignant Pleural Mesothelioma Cells.光辉霉素消耗特异性蛋白1并激活p53以介导恶性胸膜间皮瘤细胞的衰老和凋亡。
Clin Cancer Res. 2016 Mar 1;22(5):1197-210. doi: 10.1158/1078-0432.CCR-14-3379. Epub 2015 Oct 12.
4
A clinical trial of mithramycin in the treatment of advanced malignant disease.光辉霉素治疗晚期恶性疾病的临床试验。
Br J Cancer. 1968 Jun;22(2):176-83. doi: 10.1038/bjc.1968.25.
本文引用的文献
1
Triethylene melamine in the treatment of neoplastic disease; a compound with nitrogen-mustardlike activity suitable for oral and intravenous use.三乙烯三聚氰胺用于肿瘤疾病的治疗；一种具有氮芥样活性的化合物，适用于口服和静脉注射。
AMA Arch Intern Med. 1951 Apr;87(4):477-516. doi: 10.1001/archinte.1951.03810040002001.
2
MITHRAMYCIN IN THE TREATMENT OF DISSEMINATED TESTICULAR NEOPLASMS.
N Engl J Med. 1965 Jan 21;272:111-8. doi: 10.1056/NEJM196501212720301.
3
MITHRAMYCIN IN THE TREATMENT OF EMBRYONAL CANCER.
Cancer. 1964 Jul;17:938-48. doi: 10.1002/1097-0142(196407)17:7<938::aid-cncr2820170714>3.0.co;2-n.
4
Clinical trial with mithramycin.
Cancer Chemother Rep. 1963 May;29:109-10.
Zotero 插件